Brief table of contents |
|
vii | |
About the authors |
|
xv | |
Acknowledgements |
|
xvii | |
|
|
xix | |
Introduction |
|
xxi | |
|
1 Pharmacodynamics and pharmacokinetics |
|
|
1 | (14) |
|
|
1 | (1) |
|
|
2 | (1) |
|
|
3 | (1) |
|
|
4 | (1) |
|
|
5 | (1) |
|
|
6 | (1) |
|
General and molecular aspects of pharmacodynamics |
|
|
6 | (1) |
|
|
7 | (1) |
|
Agonistic and antagonistic drug action |
|
|
8 | (1) |
|
|
9 | (1) |
|
|
9 | (1) |
|
|
10 | (2) |
|
Multiple-choice questions |
|
|
12 | (1) |
|
Recommended further reading |
|
|
13 | (2) |
|
2 Adverse drug reactions and interactions |
|
|
15 | (14) |
|
|
15 | (1) |
|
|
16 | (1) |
|
Main mechanisms of drug interactions |
|
|
16 | (2) |
|
|
18 | (1) |
|
Clinical significance of drug reactions |
|
|
18 | (1) |
|
Major groups of drugs involved in adverse drug reactions |
|
|
19 | (1) |
|
Steps to minimize the effects of adverse drug reactions |
|
|
19 | (1) |
|
Age-related adverse drug reactions |
|
|
20 | (3) |
|
|
23 | (1) |
|
|
24 | (1) |
|
|
24 | (2) |
|
Multiple-choice questions |
|
|
26 | (1) |
|
Recommended further reading |
|
|
27 | (2) |
|
3 Drug calculations and numeracy skills |
|
|
29 | (12) |
|
|
29 | (1) |
|
|
30 | (1) |
|
An introduction to number |
|
|
30 | (1) |
|
|
31 | (3) |
|
|
34 | (1) |
|
Basic introduction to units and conversions |
|
|
34 | (1) |
|
Making numeracy into drug calculation |
|
|
35 | (3) |
|
|
38 | (1) |
|
|
39 | (1) |
|
Answers to questions in this chapter |
|
|
39 | (1) |
|
|
40 | (1) |
|
Recommended further reading |
|
|
40 | (1) |
|
4 Local anaesthetics and analgesics |
|
|
41 | (24) |
|
|
41 | (1) |
|
|
42 | (5) |
|
|
47 | (1) |
|
|
47 | (1) |
|
|
48 | (3) |
|
|
51 | (1) |
|
Non-steroidal anti-inflammatory drugs |
|
|
52 | (2) |
|
|
54 | (1) |
|
|
55 | (3) |
|
|
58 | (1) |
|
Drugs for neuropathic pain |
|
|
58 | (1) |
|
|
59 | (1) |
|
|
60 | (2) |
|
|
62 | (1) |
|
Multiple-choice questions |
|
|
62 | (2) |
|
Recommended further reading |
|
|
64 | (1) |
|
|
65 | (30) |
|
|
66 | (1) |
|
|
66 | (1) |
|
|
67 | (1) |
|
|
67 | (1) |
|
|
68 | (2) |
|
Interference with protein synthesis |
|
|
70 | (2) |
|
Inhibition of bacterial DNA |
|
|
72 | (1) |
|
Antibiotic resistance and antimicrobial stewardship |
|
|
73 | (1) |
|
Drugs used to treat tuberculosis |
|
|
73 | (2) |
|
|
75 | (1) |
|
Human immunodeficiency virus |
|
|
76 | (2) |
|
Other viral infections and antiviral drug treatments |
|
|
78 | (2) |
|
|
80 | (1) |
|
|
80 | (2) |
|
|
82 | (4) |
|
|
86 | (2) |
|
|
88 | (2) |
|
|
90 | (1) |
|
Multiple-choice questions |
|
|
91 | (2) |
|
Recommended further reading |
|
|
93 | (2) |
|
6 Anti-inflammatory drugs |
|
|
95 | (18) |
|
|
95 | (1) |
|
|
96 | (2) |
|
Non-steroidal anti-inflammatory drugs (NSAIDs) |
|
|
98 | (2) |
|
Cyclooxygenase pathway 2 inhibitors |
|
|
100 | (1) |
|
|
100 | (1) |
|
|
100 | (1) |
|
|
101 | (2) |
|
|
103 | (3) |
|
|
106 | (1) |
|
|
107 | (2) |
|
|
109 | (1) |
|
Multiple-choice questions |
|
|
110 | (1) |
|
Recommended further reading |
|
|
111 | (2) |
|
|
113 | (14) |
|
|
113 | (1) |
|
|
114 | (1) |
|
Blood clotting and the development of thrombosis |
|
|
115 | (1) |
|
Drugs that act on the clotting cascade |
|
|
116 | (5) |
|
Direct acting anticoagulant drugs (DOACs) |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
122 | (2) |
|
|
124 | (1) |
|
Multiple-choice questions |
|
|
125 | (1) |
|
Recommended further reading |
|
|
126 | (1) |
|
8 Drugs for respiratory conditions |
|
|
127 | (14) |
|
|
127 | (1) |
|
|
128 | (1) |
|
|
128 | (2) |
|
Drugs used in treating asthma |
|
|
130 | (4) |
|
Chronic obstructive pulmonary disease |
|
|
134 | (1) |
|
Drugs used in treating COPD |
|
|
135 | (1) |
|
|
136 | (1) |
|
|
137 | (1) |
|
|
138 | (1) |
|
Multiple-choice questions |
|
|
138 | (2) |
|
Recommended further reading |
|
|
140 | (1) |
|
9 Drugs for diabetes mellitus |
|
|
141 | (14) |
|
|
141 | (1) |
|
|
142 | (1) |
|
|
142 | (3) |
|
Medicine management of diabetes |
|
|
145 | (6) |
|
|
151 | (1) |
|
|
151 | (1) |
|
|
152 | (1) |
|
Multiple-choice questions |
|
|
152 | (2) |
|
Recommended further reading |
|
|
154 | (1) |
|
|
155 | (14) |
|
|
155 | (1) |
|
|
156 | (1) |
|
|
156 | (4) |
|
|
160 | (1) |
|
|
161 | (2) |
|
|
163 | (1) |
|
|
164 | (1) |
|
|
165 | (1) |
|
|
166 | (1) |
|
Multiple-choice questions |
|
|
167 | (1) |
|
Recommended further reading |
|
|
168 | (1) |
|
11 Drugs for Parkinson's disease and epilepsy |
|
|
169 | (12) |
|
Learning objectives -- Parkinson's disease |
|
|
169 | (1) |
|
Learning objectives -- epilepsy |
|
|
170 | (1) |
|
|
170 | (1) |
|
|
170 | (2) |
|
|
172 | (4) |
|
|
176 | (1) |
|
|
177 | (1) |
|
|
178 | (1) |
|
Multiple-choice questions |
|
|
178 | (2) |
|
Recommended further reading |
|
|
180 | (1) |
|
12 Drugs used in mental health |
|
|
181 | (20) |
|
|
181 | (1) |
|
|
182 | (1) |
|
|
182 | (1) |
|
Medicine management of anxiety |
|
|
183 | (3) |
|
|
186 | (2) |
|
Medicine management of depression |
|
|
188 | (3) |
|
|
191 | (4) |
|
|
195 | (1) |
|
|
196 | (2) |
|
|
198 | (1) |
|
Multiple-choice questions |
|
|
198 | (2) |
|
Recommended further reading |
|
|
200 | (1) |
|
13 Cancer chemotherapy and symptom management |
|
|
201 | (12) |
|
|
201 | (1) |
|
|
202 | (1) |
|
|
202 | (1) |
|
|
202 | (1) |
|
|
203 | (1) |
|
Staging and grading of cancer |
|
|
203 | (1) |
|
|
204 | (2) |
|
General side-effects of cytotoxic drugs |
|
|
206 | (2) |
|
|
208 | (1) |
|
|
209 | (1) |
|
|
210 | (1) |
|
Multiple-choice questions |
|
|
210 | (2) |
|
Recommended further reading |
|
|
212 | (1) |
|
|
213 | (12) |
|
|
213 | (1) |
|
|
214 | (1) |
|
Adherence, compliance and concordance |
|
|
214 | (1) |
|
Factors influencing effective medicine use and concordance |
|
|
215 | (2) |
|
Patient empowerment in chronic disease management |
|
|
217 | (2) |
|
|
219 | (1) |
|
|
220 | (1) |
|
|
220 | (1) |
|
|
221 | (1) |
|
Multiple-choice questions |
|
|
222 | (2) |
|
Recommended further reading |
|
|
224 | (1) |
|
15 Legal and professional issues |
|
|
225 | (16) |
|
|
225 | (1) |
|
|
226 | (1) |
|
|
226 | (1) |
|
|
226 | (1) |
|
|
227 | (1) |
|
The correct site and method of administration |
|
|
228 | (1) |
|
Covert administration of medicines |
|
|
228 | (1) |
|
Mental capacity and competence in consent |
|
|
229 | (1) |
|
|
230 | (1) |
|
|
230 | (1) |
|
|
231 | (1) |
|
Supply and administration of medicines |
|
|
232 | (1) |
|
Prescribing law and non-medical prescribing |
|
|
233 | (2) |
|
|
235 | (1) |
|
|
235 | (2) |
|
Multiple-choice questions |
|
|
237 | (2) |
|
Recommended further reading |
|
|
239 | (2) |
Conclusion |
|
241 | (2) |
Glossary |
|
243 | (2) |
Answers |
|
245 | (18) |
Index |
|
263 | |